This section is intended for UK healthcare professionals. If you are a member of the public click here. If you have been prescribed Ninlaro click here.

Why NINLARO?

Oral NINLARO is a novel approach to proteasome inhibition, designed to deliver sustained efficacy in RRMM1,2

NINLARO is the first and only oral PI licensed in combination with Rd for the treatment of adult patients with MM who have received at least 1 prior therapy1

Adding oral NINLARO to Rd:

Oral NINLARO was studied in a broad group of RRMM patients who were treated to progression2

TOURMALINE‑MM1 is the first global, phase III, double‑blind, placebo‑controlled study investigating an oral PI in RRMM patients. The trial compared NINLARO + Rd as part of an all oral regimen versus placebo + Rd in 722 RRMM patients treated with 1-3 prior therapies2

Watch Professor Moreau present the key findings from the TOURMALINE‑MM1 study

Patient support

Takeda Oncology has developed a range of information and support tools designed for patients prescribed NINLARO

Click here to find out more about the support offered to NINLARO patients